Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 11/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17729049 | 0.83 | PTPN2 (0.52) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL19117951 | 0.81 | RORC (0.53) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL19118311 | 0.81 | RORC (0.53) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL13238912 | 0.78 | ALDH1A1 (0.53) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL19118620 | 0.75 | POLB (0.47) | MEN1KMT2AAR | |
| SCHEMBL380969 | 0.75 | ALDH1A1 (0.61) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL18197007 | 0.73 | NPC1 (0.40) | MEN1KMT2APTPN2PTPN1PTPN6 | |
| SCHEMBL173502 | 0.73 | NAMPT (0.46) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL2711455 | 0.71 | DPP4 (0.44) | MEN1KMT2ANPC1RAB9AAR | |
| SCHEMBL31616260 | 0.71 | USP2 (0.40) | MEN1KMT2APTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | MEN1 3066/4885KMT2A 734/4885PTPN2 1231/4885 |
| US-10000488-B2 | Heterocyclic compound | RORC, RORB, RORA | MEN1 3066/4885KMT2A 734/4885PTPN2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.